(Q39359690)

English

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

scientific article published on 19 September 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

phase III clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

object named as

David J Kerr

15

0 references

object named as

Enric Domingo

14

0 references

13

object named as

Ian Tomlinson

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

6

object named as

Peter Hewett

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Elaine C Johnstone

4

object named as

Elaine Johnstone

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Rachel S Kerr

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sharon Love

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Beverly Falcon

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Andrew Weaver

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

David Church

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Claire Scudder

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sarah Pearson

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Patrick Julier

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Francesco Pezzella

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

19 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1543-1557

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-content multiplexed tissue imaging and quantification for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of new morphometric parameters of neoangiogenesis in human colorectal cancer using confocal laser endomicroscopy (CLE) and targeted panendothelial markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930172-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30172-3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39359690&oldid=1836074686"